Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation

Heart

Volumn 91, Issue 6, 2005, Pages 759-763

  Lip, Gregory Y H ^a   Pearce, L A ^b   Chin, B S P ^a   Conway, D S G ^a   Hart, R G ^c  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b Axio Research Corporation   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PADGEM PROTEIN; VON WILLEBRAND FACTOR; WARFARIN;

AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STROKE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VON WILLEBRAND FACTOR; WARFARIN;

EID: 20044384016     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.036160     Document Type: Article

References (33)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Atrial fibrillation investigators. Arch Intern Med 1994;154:1449-57.
2. Leung DY, Black IW, Cranney GB, et al. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994;24:755-62.
3. SPAF Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Stroke prevention in atrial fibrillation investigators. Ann Intern Med 1992;116:6-12.
4. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1997;75:1004-11.
5. Siostrzonek P, Koppensteiner R, Gossinger H, et al. Hemodynamic and hemorheologic determinants of left atrial spontaneous echo contrast and thrombus formation in patients with idiopathic dilated cardiomyopathy. Am Heart J 1993;125:430-4.
6. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-4.
7. Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999;33:1424-6.
8. Gibbs CG, Blann AD, Watson RDS, et al. Abnormalities of hemorheological, endothelial and platelet function in patents with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and b-blocker therapy. Circulation 2001;103:1740-51.
9. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-12.
10. Lip GYH, Blann AD. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65.
11. Blann AD, Lip GYH. Is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997;128:135-8.
12. Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation. Circulation 2002;106:1902-7.
13. Conway DSG, Pearce LA, Chin BSP, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvavular atrial fibrillation. Circulation 2003;107:3141-5.
14. SPAF Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. SPAF investigators. Lancet 1996;348:633-8.
15. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003;138:831-8.
16. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547-53.
17. Roth GJ. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991;77:5-19.
18. Wagner DD. Cell biology of von Willebrand factor. Ann Rev Cell Biol 1990;6:217-40.
19. Luscher TF. The endothelium and cardiovascular disease: a complex relation. N Engl J Med 1994;330:1081-3.
20. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001;37:1436-42.
21. SPAF Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. The stroke prevention in atrial fibrillation investigators. Ann Intern Med 1992;116:1-5.
22. Van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-43.
23. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham heart study. JAMA 2003;290:1049-56.
24. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990;82:1724-9.
25. Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to nemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-66.
26. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 1990;323:326-41.
27. Kalaria VG, Passannante MR, Shah T, et al. Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy. Am Heart J 1998;135:215-20.
28. Blondheim DS, Jacobs LE, Kotler MN, et al. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Heart J 1991;122:763-71.
29. Maze SS, Kotler MN, Parry WR. Flow characteristics in the dilated left ventricle with thrombus. J Am Coll Cardiol 1989;13:873-81.
30. Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high risk patients with non-rheumatic atrial fibrillation. Am J Cardiol 1993;72:840-3.
31. Lowe GDO, Forbes CD. Rheology of cardiovascular disease. In: Lowe GDO, eds. Clinical blood rheology, vol II. Boca Raton: CRC Press, 1988:113-40.
32. Bonfanti R, Furie BC, Furie B, et al. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989;73:1109-12.
33. Li-Saw-Hee FL, Blann AD, Lip GYH. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol 2000;35:1926-31.